Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1991 1
1992 1
1994 3
1995 3
1996 1
1998 2
1999 3
2000 2
2001 7
2002 7
2003 4
2004 4
2005 3
2006 5
2007 8
2008 3
2009 7
2010 13
2011 8
2012 15
2013 13
2014 20
2015 20
2016 31
2017 13
2018 14
2019 20
2020 25
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 22726074

240 results
Results by year
Filters applied: . Clear all
Page 1
Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.
Vicente-Valor MI, Garcia-Llopis P, Mejia Andujar L, Antonino de la Camara G, García del Busto N, Lopez Tinoco MJ, Quintana Vergara B, Peiro Vilaplana C, Dominguez Moran JA, Sánchez Alcaraz A. Vicente-Valor MI, et al. J Clin Pharm Ther. 2013 Feb;38(1):71-3. doi: 10.1111/j.1365-2710.2012.01365.x. Epub 2012 Jun 21. J Clin Pharm Ther. 2013. PMID: 22726074
Successful intrathecal baclofen therapy for seronegative stiff-person syndrome: a case report.
Ho BL, Shih PY. Ho BL, et al. Acta Neurol Taiwan. 2008 Sep;17(3):172-6. Acta Neurol Taiwan. 2008. PMID: 18975523
Advances in the management of multiple sclerosis spasticity: recent clinical trials.
Fernández O. Fernández O. Eur Neurol. 2014;72 Suppl 1:9-11. doi: 10.1159/000367616. Epub 2014 Sep 26. Eur Neurol. 2014. PMID: 25278117 Free article.
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Sastre-Garriga J, Vila C, Clissold S, Montalban X. Sastre-Garriga J, et al. Expert Rev Neurother. 2011 May;11(5):627-37. doi: 10.1586/ern.11.47. Epub 2011 Apr 1. Expert Rev Neurother. 2011. PMID: 21456949 Review.
Focal stiff-person syndrome.
Fiol M, Cammarota A, Rivero A, Pardal A, Nogués M, Correale J. Fiol M, et al. Neurologia. 2001 Feb;16(2):89-91. Neurologia. 2001. PMID: 11257937
Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Haupts M, Vila C, Jonas A, Witte K, Álvarez-Ossorio L. Haupts M, et al. Eur Neurol. 2016;75(5-6):236-43. doi: 10.1159/000445943. Epub 2016 May 10. Eur Neurol. 2016. PMID: 27160412 Clinical Trial.
Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Vermersch P, Trojano M. Vermersch P, et al. Eur Neurol. 2016;76(5-6):216-226. doi: 10.1159/000449413. Epub 2016 Oct 13. Eur Neurol. 2016. PMID: 27732980
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ, Nurmikko TJ, Young CA. Rog DJ, et al. Clin Ther. 2007 Sep;29(9):2068-79. doi: 10.1016/j.clinthera.2007.09.013. Clin Ther. 2007. PMID: 18035205 Clinical Trial.
THC:CBD spray and MS spasticity symptoms: data from latest studies.
Rekand T. Rekand T. Eur Neurol. 2014;71 Suppl 1:4-9. doi: 10.1159/000357742. Epub 2014 Jan 22. Eur Neurol. 2014. PMID: 24457846 Free article. Review.
Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity.
Keating GM. Keating GM. Drugs. 2017 Apr;77(5):563-574. doi: 10.1007/s40265-017-0720-6. Drugs. 2017. PMID: 28293911 Review.
240 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback